Skip to content
Parakho

Vivimed Labs Ltd

NSE VIVIMEDLABBSE 532660

Q4 FY26

Revenue
₹12.00 Cr
Profit after tax
₹-146.04 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ4 FY26vs a year agoFY26
Revenue from operations12.00−53.15%69.99
Other income5.75+36.28%6.32
Total income17.75−40.51%76.31
Employee benefit expense9.97+13.46%24.97
Finance costs0.95−45.57%4.17
Depreciation & amortisation11.51+109.22%26.05
Total expenses163.65+369.50%251.56
Profit before tax-145.90−2,804.02%-175.25
Tax expense0.14+21.24%0.14
Profit after tax-146.04−2,742.81%-175.38
Total comprehensive income-146.04−2,742.81%-175.38
Earnings per share
Earnings per share, basic₹-17.74₹-21.15
Earnings per share, diluted₹-17.22₹-20.53

Q4 FY26 and FY26 — from the company’s filing with NSE. Source

Q4 FY25, the year-ago base — from the company’s filing with NSE. Source

Earnings call

Vivimed Labs Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 17 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 17 Aug 2026.